Partners Viii, L.P.Alta Par... Net Worth

The estimated Net Worth of Partners Viii, L.P.Alta Par... is at least $4.64 million dollars as of 21 October 2014. Partners Par owns over 500,000 units of Esperion Therapeutics stock worth over $4,644,984 and over the last 11 years Partners sold ESPR stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Partners Par ESPR stock SEC Form 4 insiders trading

Partners has made over 2 trades of the Esperion Therapeutics stock since 2013, according to the Form 4 filled with the SEC. Most recently Partners bought 500,000 units of ESPR stock worth $10,000,000 on 21 October 2014.

The largest trade Partners's ever made was buying 500,000 units of Esperion Therapeutics stock on 21 October 2014 worth over $10,000,000. On average, Partners trades about 367,857 units every 239 days since 2013. As of 21 October 2014 Partners still owns at least 2,552,189 units of Esperion Therapeutics stock.

You can see the complete history of Partners Par stock trades at the bottom of the page.

Insiders trading at Esperion Therapeutics

Over the last 11 years, insiders at Esperion Therapeutics have traded over $197,978,412 worth of Esperion Therapeutics stock and bought 6,755,593 units worth $134,445,709 . The most active insiders traders include Patrick G Enright, Target N Vbb Biotech Ag Bio... et Nicole Vitullo. On average, Esperion Therapeutics executives and independent directors trade stock every 33 days with the average trade being worth of $145,621. The most recent stock trade was executed by Eric Warren on 19 August 2024, trading 211 units of ESPR stock currently worth $411.

What does Esperion Therapeutics do?

esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.

Complete history of Partners Par stock trades at Esperion Therapeutics

Esperion Therapeutics executives and stock owners

Esperion Therapeutics executives and other stock owners filed with the SEC include:

• Timothy Mayleben,
  President, Chief Executive Officer, Director
• Mark Glickman,
  Chief Commercial Officer
• Richard B. Bartram,
  CFO & Corp. Sec.
• Tracy Woody,
  Independent Director
• Sheldon L. Koenig,
  Pres, CEO & Director
• Richard Bartram,
  Chief Financial Officer
• Dr. JoAnne Micale Foody FACC, M.D.,
  Chief Medical Officer
• Nicole Vitullo,
  Lead Independent Director
• Jay Shepard,
  Independent Director
• Daniel Janney,
  Independent Director
• Jeffrey Berkowitz,
  Director
• Mark McGovern,
  Independent Director
• Antonio Gotto,
  Independent Director
• Alan Fuhrman,
  Independent Director
• Ashley Hall,
  Chief Development Officer
• Eric J. Warren R.Ph.,
  Chief Commercial Officer
• Betty Jean Swartz,
  Chief Strategy Officer
• Benjamin O. Looker,
  Gen. Counsel
• Jerry Penn,
  Exec. Director of Managed Care
• Roberta Peterson,
  Sr. Director of National Accounts
• April Seiler,
  Sr. Director of Project Management
• Dr. Joanne Micale Foody FACC, M.D.,
  Chief Medical Officer
• Renee Marotta,
  Head of Marketing
• Keith F. Lenden,
  VP of Corp. Devel. & Strategy
• Benjamin Church,
  Head of Corp. Communications & Investor Relations
• Dr. Kenneth J. Fiorelli,
  Chief Technical Operations Officer
• Patrick G Enright,
  Director
• Gilbert S Omenn,
  Director
• Dov A Md Goldstein,
  Director
• Mary Mc Gowan,
  Chief Medical Officer
• Scott Braunstein,
  Director
• Roger S Newton,
  Executive Chairman, CSO
• Seth H. Z. Fischer,
  Director
• Capital, Llc Boxer Asset Ma...,
  
• Target N Vbb Biotech Ag Bio...,
  
• Partners Viii, L.P.Alta Par...,
  
• Kathleen K Schoemaker,
  10% owner
• Partners Viii, L.P. Alta,
  10% owner
• Capital Ii Lpaisling Capita...,
  
• Parters Vii L Pblair James ...,
  
• Capital Partners, Llc Longi...,
  
• Noah L. Rosenberg,
  Chief Medical Officer
• James C Blair,
  10% owner
• Parters Vii L P Domain,
  10% owner
• Vii Associates Lp Dp,
  10% owner
• Brian H Dovey,
  10% owner
• Brian K Halak,
  10% owner
• Jesse I Treu,
  10% owner
• Louis G Lange,
  Director
• Joanne M. Foody,
  Chief Medical Officer
• Sheldon L. Koenig,
  President and CEO
• Benjamin Looker,
  General Counsel
• Eric Warren,
  Chief Commercial Officer
• Stephen Rocamboli,
  Director
• Benjamin Halladay,
  Chief Financial Officer
• J Martin Carroll,
  Director